FDA Approves Regeneron's Rare-Disease Drug Pasatru Despite Small Market Potential
The FDA approved Regeneron Pharmaceuticals' (NASDAQ:REGN) drug Pasatru for the treatment of fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder. The approval followed a successful Phase 3 trial showing a significant reduction in abnormal bone lesions compared to placebo. However, due to the extremely small patient population—estimated at around 800–900 globally—the drug is unlikely to significantly impact Regeneron's earnings. Regeneron reported strong second-quarter financial results with revenue of $4.29 billion and non-GAAP diluted EPS reaching $14.29, driven by its major products like Dupixent and Eylea HD. Despite the regulatory win for Pasatru, analysts note that commercial potential is limited due to existing competition from drugs such as Ipsen's Sohonos approved in 2023. The approval highlights Regeneron’s ability to recover a drug program after earlier setbacks but may have more long-term value than immediate financial impact. The company plans pediatric trials for Pasatru later this year, which could expand its market potential.
